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 Abstract 
Background Liver function tests might predict the risk of type 2 diabetes. An 
independent study evaluating utility of these markers compared with an existing 
prediction model is yet lacking. 
Methods We performed a case-cohort study, including random subcohort (6.5%) 
from 38,379 participants with 924 incident diabetes cases (the Dutch contribution to 
the European Prospective Investigation Into Cancer and Nutrition, EPIC-NL, the 
Netherlands), and another population-based cohort study including 7,952 
participants with 503 incident cases (the Prevention of Renal and Vascular End-stage 
Disease, PREVEND, Groningen, the Netherlands). We examined predictive value of 
combination of the liver function tests (gamma-glutamyltransferase, alanine 
aminotransferase, aspartate aminotransferase and albumin) above validated models 
for 7.5-year risk of diabetes (the Cooperative Health Research in the Region of 
Augsburg, the KORA study). Basic model includes age, sex, BMI, smoking, 
hypertension and parental diabetes. Clinical models additionally include glucose and 
uric acid (model1) and HbA1c (model2).  
Results In both studies, addition of Liver function tests to the basic model improved 
the prediction (C-statistic by~0.020; NRI by~9.0%;P<0.001). In the EPIC-NL case-
cohort study, addition to clinical model1 resulted in statistically significant 
improvement in the overall population (C-statistic=+0.009; P<0.001; NRI=8.8%; 
P<0.001), while addition to clinical model 2 yielded marginal improvement limited to 
men (C-statistic=+0.007; P=0.06; NRI=3.3%; P=0.04). In the PREVEND cohort study, 
addition to clinical model 1 resulted in significant improvement in the overall 
population (C-statistic change=0.008; P=0.003; NRI=3.6%; P=0.03), with largest 
improvement in men (C-statistic change=0.013; P=0.01; NRI=5.4%; P=0.04). In 
PREVEND, improvement compared to clinical model 2 could not be tested because of 
lack of HbA1c data. 
Conclusions Liver function tests modestly improve prediction for medium-term risk 
of incident diabetes above basic and extended clinical prediction models, only if no 
HbA1c is incorporated. If data on HbA1c are available, Liver function tests have little 
incremental predictive value, although a small benefit may be present in men. 
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 Introduction 
 Change in liver function tests is considered as surrogate marker of liver injury and 
nonalcholic fatty liver disease (NAFLD) 1. Previous studies have demonstrated that 
circulating concentration of liver function tests like gamma-glutamyltransferase 
(GGT), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are 
increased in individuals with insulin resistance and the metabolic syndrome 1-3. In 
addition, these components of liver function tests have been shown to be positively 
associated with the  risk of future type 2 diabetes 1, 4. A recent meta-analysis on this 
topic showed that both elevated ALT and GGT were associated with increased risk of 
diabetes, while GGT might be a stronger risk factor than ALT 4.  
However, there is only a limited number of studies that examine the predictive 
value of liver function tests for the risk of future diabetes in terms of essential 
measures of prediction, such as the C-statistic to assess discrimination between 
people who develop diabetes and those who don’t 5-8. These studies mainly 
developed 6, 7 or updated 5 clinical prediction models by incorporating one or two 
components of liver function tests in each models. It is important to note that the 
predictive value of liver function tests was examined in combination with other 
(bio)markers and in the same data set that was used to develop the original models 5-
7. Of these, 2 studies showed improvement in prediction when GGT plus glycaemia 
indices were added to a basic model consisting only of data that can be derived 
without need for taking blood samples 6, 7. In another study, a combination of GGT, 
ALT, triglycerides and HDL cholesterol improved discrimination above a diabetes 
risk score including HbA1c and glucose 5.  
So, whether liver function tests have incremental predictive value above 
validated model(s) is still unclear. An independent study evaluating utility of these 
markers of liver function when incorporated in an existing prediction model is 
needed to answer this question 9, 10. Recently, we validated and updated German 
prediction models from the Cooperative Health Research in the Region of Augsburg 
(KORA) study in a Dutch general population cohort 11, 12. In the current study, we 
addressed the incremental predictive value of liver function tests for the risk of future 
type 2 diabetes when compared with the KORA models 12. To do so, we analysed 
data from two independent cohorts separately. In each cohort, we performed 
analyses in the total population and sex-stratified subgroups to account for potential 
sex differences in the prediction performance of each model 6, 11, 13.  
Methods 
Study design and populations  
We used data from two cohorts of general population in the Netherlands: 1) the 
Dutch contribution to the European Prospective Investigation Into Cancer and 
Nutrition (EPIC-NL) study; and 2) the Prevention of Renal and Vascular End-stage 
85
 Disease (PREVEND) study. Details of each study design and recruitment of 
participants have been published previously 14, 15.  
In brief, the EPIC-NL cohort (n = 40,011) includes the Monitoring Project on 
Risk Factors for Chronic Diseases (MORGEN) and Prospect cohorts, initiated between 
1993 and 1997. Prospect is a prospective cohort study of 17,357 women aged 49–70 
years who participated in a breast cancer screening programme. The MORGEN 
cohort consists of 22,654 men and women aged 20-64 years who were recruited 
through random population sampling in three Dutch towns (Amsterdam, Maastricht 
and Doetinchem). A new random sample of about 5,000 participants was examined 
each year. We excluded 615 individuals with prevalent type 2 diabetes and 1,017 with 
missing follow-up or who did not consent to linkage with disease registries, leaving 
38,379 individuals in the full cohort. In a 6.5% baseline random sample (n=2,604) with 
biochemical measurements 14, similar exclusion criteria were applied. After 
exclusions, 2,506 individuals (including 79 incident diabetes cases) from the random 
sample and 924 incident diabetes cases in the full cohort remained for the case-cohort 
study 16. We used this case-cohort sample for all analyses.  
In brief, the baseline PREVEND cohort (n=8,592) was recruited from 
inhabitants (aged 28–75 years) of the city of Groningen, the Netherlands. Baseline 
measurements were performed between 1997 and 1998. The PREVEND cohort 
included a total of 6,000 individuals with a morning urinary albumin concentration of 
10 mg/l or greater and a random control sample of individuals with a urinary 
albumin concentration of less than 10 mg/L (n=2,592). Overall, we excluded 336 
individuals with prevalent type 2 diabetes and 277 with missing data on follow-up, 
leaving 7,979 individuals for the full cohort study. We used this full cohort sample for 
all analyses. 
Ethics Statement 
All participants gave written informed consent prior to study inclusion. All cohort 
studies complied with the Declaration of Helsinki and were approved by local 
medical ethics committees. 
Measurements of biomarkers   
In the EPIC-NL study, the general questionnaire contained questions on demographic 
characteristics and risk factors for the presence of chronic diseases. Body weight, 
height and waist and hip circumference were measured according to standard 
procedures. Hypertension was defined based on self-report of diagnosis by a 
physician, measured hypertension (≥140 mmHg systolic blood pressure or ≥90 
mmHg diastolic blood pressure) or the use of blood pressure-lowering medication. 
Non-fasting blood samples were collected at baseline from all participants. HbA1c 
was measured in erythrocytes using an immunoturbidimetric latex test. Glucose and 
uric acid were measured using enzymatic methods. AST, ALT and GGT were 
measured using enzymatic methods and albumin by a colorimetric method 14.  
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 In the PREVEND study, the participants underwent two outpatient visits to 
assess baseline data on demographics, anthropometric measurements, cardiovascular 
risk factors, health behaviours, and medical family history and to collect two 24-hour 
urine samples on 2 consecutive days. Blood pressure values are given as the mean of 
the last two recordings of both visits as this provides the values after stabilization of 
blood pressure. Plasma glucose was measured by dry chemistry (Eastman Kodak, 
Rochester, New York). All liver function tests were measured by a standardized 
enzymatic method (Modular P; Roche Diagnostics, Indianapolis, IN).  
  
Definition of main outcome 
In the EPIC-NL study, potential incident type 2 diabetes was self-reported via two 
follow-up questionnaires at 3- to 5-year intervals in the MORGEN and Prospect 
cohort. In the Prospect cohort, a urinary glucose strip test was sent along with the 
first follow-up questionnaire as a screening method. Diagnoses of type 2 diabetes 
were also obtained from the Dutch Center for Health Care Information, which holds a 
standardized computerized register of hospital discharge diagnoses. Follow-up was 
complete until January 1, 2006. Potential cases identified by these methods were 
verified against general practitioner (MORGEN and Prospect) or pharmacist records 
(Prospect only). We defined type 2 diabetes as being present when the diagnosis was 
confirmed by either of these methods. For 89% of participants with potential diabetes, 
verification information was available, and 72% were verified as having type 2 
diabetes and were included as cases of type 2 diabetes in this analysis 17. The rest of 
individuals were considered as non-cases. 
In the PREVEND study, incident cases of diabetes were ascertained as 
described previously 18. In brief, incident diabetes was considered present if one or 
more of the following criteria were met: 1) a fasting plasma glucose of ≥7.0mmol/l 
(126mg/dl) or random sample plasma glucose ≥ 11.1 mmol/l (200mg/dl); 2) self-
reported physician’s diagnosis; 3) use of glucose-lowering agents according to a 
central pharmacy registration. 
Statistical analysis 
First, we examined the association between the components of liver function tests 
(including GGT, ALT, AST and albumin) and the risk of future diabetes. For liver 
function tests, we used logarithm transformation with base 2 (log2) to allow for 
interpretation of results per increase of 100% of values of each component. We used 
Cox proportional-hazards regression in the EPIC-NL study which was adapted for 
case-cohort analysis. We used logistic regression in the PREVEND full cohort study, 
because the events have been detected at regular screening visits or shortly thereafter. 
Thus, estimated survival and hazards can not be accurately calculated by this type of 
follow-up. In step 1, we calculated age and sex-adjusted hazard ratios (HRs) and odd 
ratios with 95% CIs for the risk of diabetes by doubling of concentrations of each liver 
function tests (per log2 unit increase). In step 2, we adjusted for age, sex, parental 
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 diabetes, body mass index (BMI), smoking status, hypertension, glucose and uric 
acid. In step 3, we further adjusted for HbA1c. This could only be done in the EPIC-
NL case-cohort study, because data on HbA1c were not available in the PREVEND 
study.  
To account for the case-cohort design in the EPIC-NL study, we applied an 
extrapolation approach which extends the case-cohort data to the size of the entire 
cohort 19. This is achieved by extrapolating the non-cases of the random sample (i.e., 
total random sample of 2,506 individuals minus 79 cases) to the number of non-cases 
in the full cohort (i.e., total sample of 38,379 individuals minus 924 cases). To do so, 
we substituted the non-cases of the full cohort (n = 37,455) by a random 
multiplication of non-cases of the random sample (n = 2,427). We have previously 
described and validated this approach 20. 
In the second part of this study, we computed the probability of getting 
diabetes using the KORA basic model which was previously validated and updated 
in the PREVEND cohort 11. As previously described 11, we recalibrated the original 
KORA model by means of logistic regression to derive the intercept and the 
calibration slope in the PREVEND cohort study. We also adjusted for the difference in 
incident diabetes between the KORA and the EPIC-NL cohorts by fitting the original 
KORA model in the EPIC-NL case-cohort study 21. Figure S1 (a, b) depicts the 
agreement between the predicted 7.5-year risk and observed risk of type 2 diabetes 
after recalibration in each cohort. The basic model included data on age, sex, parental 
diabetes, body mass index (BMI), smoking status and hypertension 12. Clinical model 
1 included additional data on glucose plus serum uric acid; and in clinical model 2 we 
further added HbA1c. As the original KORA models have been developed for a time 
period of risk prediction of 7.5 years, we examined the incremental predictive value 
of liver function tests also for the 7.5-year risk of developing type 2 diabetes. 
Therefore, participants who developed diabetes after more than 7.5 years of follow-
up were included in 7.5-year prediction as non-cases. We examined added predictive 
value of 1) each component alone, 2) combination of GGT+ALT and 3) a panel of 
GGT, ALT, AST and albumin. We assessed improvement of type 2 diabetes 
prediction in terms of discrimination by calculating the C-statistic with 95%CI, and 
reclassification by calculating integrated discrimination improvement (IDI) and net 
reclassification improvement (NRI) 22, 23. To calculate the NRI, cut-off values for risk 
categories have to be defined. In previous studies, a number of risk categories for the 
10-year risk of cardiovascular disease 23, 24 or type 2 diabetes 25, 26 have been reported. 
In the present study, we slightly modified these cut-off values according to the 
shorter time period (and hence the lower average observed risk) 25, 26, using cut-off 
values of <4% for low-risk, 4%-8% for intermediate-risk and ≥8% for high-risk.  
In the EPIC-NL case-cohort study, for most predictors <1% of data were 
missing; however, missing values occurred in 5% for parental history of diabetes, and 
20.5% for glucose levels. Because an analysis of only the completely observed data 
may often lead to biased results, we imputed these missing values using single 
imputation and predictive mean matching 27. As the percentage of missing values for 
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 the non-fasting glucose concentration was relatively high, we repeated our analyses 
using only data from the MORGEN cohort, in which less than 10% of values for non-
fasting glucose concentration were missing, as a sensitivity analysis. In the PREVEND 
cohort study, for most variables, <1% were missing, whereas this was up to 7.5% for 
self-reported variables. To account for missing values, we used a similar approach to 
that of the EPIC-NL study. Table S1 in supporting information shows the number of 
missing values for all variables incorporated in each model. We also used a weighted 
method to compensate for baseline enrichment of the PREVEND participants with 
high urinary albumin concentration (>10 mg/l). All the statistical analyses were 
carried out using IBM SPSS 19.0 and R version 2.13.1 (Vienna, Austria) for Windows 
(http://cran.r-project.org/). 
Results 
Baseline clinical characteristics 
We summarize baseline characteristics of the participants of each study in Table 1. 
Participants of the EPIC-NL study were more likely to be women, and to have 
hypertension and parental history of diabetes, whereas participants of the PREVEND 
study were more likely to be smoker and had slightly higher uric acid and albumin 
on average. In the EPIC-NL cohort study, we ascertained and validated 924 (2.4%) 
incident cases of type diabetes during a median follow-up of 10.2 years (over 387,000 
person-years). In the PREVEND cohort study, we ascertained 503 (6.3%) incident 
cases during a median follow-up of 7.7 years (over 60,186 person-years).  
Liver function tests and type 2 diabetes 
Table 2 depicts the associations between components of liver function tests and the 
risk of diabetes, calculated per 100% increase of marker concentrations in total 
populations and in sex-stratified subgroups. In the EPIC-NL case-cohort study, the 
multivariable-adjusted HRs (95%CI) for the risk of diabetes were 1.49 (1.37-1.61), 1.22 
(1.09-1.37), 0.97 (0.81-1.17) and 0.34 (0.21-0.54) per doubling concentrations of GGT, 
ALT, AST and albumin, respectively. In the PREVEND cohort study, the 
multivariable-adjusted ORs (95%CI) for the risk of diabetes were 1.22 (1.09-1.38), 1.29 
(1.11-1.50), 1.16 (0.89-1.50) and 0.31 (0.87-1.05) per 100% increase of concentrations of 
GGT, ALT, AST and albumin, respectively. The associations between liver function 
tests and the risk of diabetes did not significantly differ by sex in both cohorts (P>0.1 
for interaction). In the EPIC-NL case-cohort study, stratified analysis by sex showed 
that the direction of the association between albumin and diabetes risk was changed 
in men after adjustment for age, BMI with family history of diabetes (also for the 
KORA basic model plus glucose) (data not shown).   
Predictive value of liver function tests 
In the EPIC-NL case-cohort study, the basic model showed a C-statistic of 0.823 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 improved the C-statistic of the basic model (C-statistic change= 0.024; P<0.001) and 
led to an IDI of 0.011 (P<0.001) and NRI of 9.5% (P<0.001). After addition of each 
component of liver function tests alone to the basic models, the C-statistic changes 
were 0.014 (P<0.001), 0.006 (P<0.001), 0.001 (P=0.15) and 0.002 (P=0.13) for GGT, ALT, 
AST and albumin, respectively. Addition of liver function tests also improved 
prediction for clinical model 1 (C-statistic change=0.009; P<0.001; NRI=8.8%; 
P<0.001). Although addition of liver function tests did not improve prediction for 
clinical model 2 in the total population (C-statistic change=0.002; P=0.61; NRI=1.2%; 
P=0.3), a slight improvement, although not statistically significant in terms of 
discrimination, was observed when men were considered separately (C-statistic 
change=0.007; P=0.06; NRI=3.3%; P=0.04). In women, addition of liver function tests 
improved prediction for clinical model 1, but did not improve for clinical model 2 
(Table 3). 
In the PREVEND cohort study, the basic model showed a C-statistic of 0.775 
(0.757-0.793). Addition of liver function tests improved the C-statistic of the basic 
model (C-statistic change= 0.019; P<0.001) and led to an IDI of 0.01 (P<0.001) and NRI 
of 8.7% (P<0.001). After addition of each component of liver function tests alone to 
the basic models, the C-statistic changes were 0.013 (P<0.001), 0.011 (P=0.002), 0.002 
(P=0.29) and 0.0001 (P=0.98) for GGT, ALT, AST and albumin, respectively.  Addition 
of liver function tests improved prediction for clinical model 1 in the total population 
(change of C-statistic=0.008; P=0.003; NRI=3.6%; P=0.03), with the largest change in 
men (C-statistic change=0.013; P=0.01; NRI=5.4%; P=0.04) (Table 1). In both cohorts, 
predictive power slightly increased when we added more liver function tests to the 
KORA model. For example, in the EPIC-NL study, NRI increased from 6% to 9.5% 
when we added the panel of all four available liver function tests to the KORA model 
rather than only the combination of GGT+ALT (Table  S2). 
In both cohorts, the basic and clinical models provided slightly better 
discrimination in women than in men. For example, in the EPIC-NL study, the C-
statistic of the basic model was 0.826 (0.810-0.841) in women while this was 0.818 
(0.788-0.847) in men. For clinical model 2, the C-statistic was 0.933 (0.923-0.944) in 
women while this was 0.877 (0.854-0.905) in men. In the PREVEND study, the C-
statistic of the basic model was 0.822 (0.95-0.848) in women while this was 0.724 
(0.697-0.750) in men. For clinical model 1, the C-statistic was 0.883 (0.859-0.907) in 
women while this was 0.809 (0.785-0.832) in men (Table 3). 
In a sensitivity analysis, our results using data only from the MORGEN cohort 
with less than 10% missing values for non-fasting glucose were comparable with our 
results using both cohorts of the EPIC-NL study. Addition of liver function tests 
improved the C-statistic of the basic KORA model (C-statistic change= 0.020; P<0.001) 
and led to an IDI of 0.006 (P<0.001) and NRI of 9.3% (P<0.001). Addition of liver 
function tests did not improve prediction for clinical model 2 (C-statistic 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
  
   



















































































































































































































































































































































































   
   
  
   

















































































































































































































































































































































































   
   
  
   
















































































































































































































































































































































































































































In this prospective analysis, we examined whether addition of liver function tests 
could be useful to improve prediction of developing type 2 diabetes above the basic 
and clinical models in two independent large population-based cohorts. We observed 
that addition of liver function tests improved prediction modestly only for a basic 
model without biomarkers in terms of discrimination and reclassification in each 
cohort. Furthermore, addition of liver function tests led to small but statistically 
significant improvements in prediction based on a clinical model incorporating 
glucose and serum uric acid, but not if the clinical model also includes HbA1c. 
However, there was a slightly better improvement in prediction for men.  
Several studies have been performed to investigate the associations of liver 
function tests with type 2 diabetes and its related outcomes 1, 4. However, just a 
limited number of studies aimed to examine the incremental predictive value of these 
markers over available prediction models. A analysis of the EPIC-Potsdam cohort 
showed that a combination of triglycerides, HDL- cholesterol, GGT and ALT further 
improved prediction based on the German diabetes risk score incorporating glucose 
and HbA1c in the same population in which they had previously developed that risk 
score 5. In the DESIR study, a model with GGT and glucose showed an improved 
prediction in men compared with a basic model incorporating data on smoking, waist 
circumference and hypertension 6. Recently, the British Heart Study showed that a 
clinical model incorporating GGT plus HbA1c improved prediction compared with a 
basic simple model. However, addition of GGT itself had little improvement above a 
clinical model incorporating glucose, HDL cholesterol and triglyceride 7. Of note, it is 
particularly important for the value of biomarkers to be examined in an independent 
setting, because the improvement in measures of prediction can be overestimated if 
the same population is used for development and evaluation of the incremental value 
of new biomarkers 10, 28, 29. In our study, we scientifically evaluated incremental 
predictive value of liver function tests in two independent Dutch populations because 
we intended to validate our findings in another setting as well. In this way, we took 
advantage of using a different case mix and slightly different measurement of 
diabetes between two cohorts 28. 
Furthermore, we also did this analysis for women and men separately to take 
into account potential sex differences in the risk prediction of diabetes 6, 30. For 
example, we and others have shown that prediction models might have a slightly 
better performance to identify women at high risk 6, 11, 13. We observed no differences 
in the incremental predictive value of liver function tests above the basic and clinical 
model incorporating glucose plus uric acid between women and men. However, 
there was a statistically significant improvement in prediction only in men when we 
added liver function tests to a clinical model incorporating glucose plus uric acid plus 
HbA1c. At population level, it is true that a prediction model, like the KORA basic 
model, incorporating 6 predictors, performs well to identify the individuals at high 
risk of future diabetes for 7.5 years. In our study, addition of liver function tests did 
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 hardly result in any improvement of prediction once additional data on glycaemia 
indices were included. The reason why improvements in predictions were limited in 
the latter clinical models is that the glycaemia indices are integral parts of the clinical 
outcome of interest, i.e., diabetes. Diabetes itself is defined by certain cut-offs for 
glucose and/or HbA1c 31.  
Like previous studies 1, 4, we demonstrated significant associations of some 
components of liver function tests with the risk of type 2 diabetes. The associations 
were independent of common risk factors but addition of liver function tests only 
minimally to modestly improve the risk prediction of disease. In other words, the 
absolute difference of certain (bio)markers between individuals who develop and 
those who remain free of diabetes at a population level is not likely to resolve 
whether a (bio)marker can be useful for prediction 29. In fact, on an individual level, 
the range of marker levels between cases and non-cases overlap, limiting its 
incremental predictive value 29, 32. In contrast, although a certain (bio)marker does not 
show statistical significance in an etiologic relation, it might still have incremental 
predictive value in combination with other predictors. So from that point of view it is 
reasonable to examine all four components of liver function tests in each model.  
All the basic and clinical models showed slightly better discrimination 
performance in the EPIC-NL case-cohort study than in the PREVEND cohort study 
overall and particularly in men. This difference might be explained by differences in 
heterogeneity between these two populations 33. Larger heterogeneity between 
individuals make it easier to differentiate between those at high and low risk and 
may thus lead to higher C-statistics. For example, variables like age and sex may have 
larger heterogeneity in the EPIC-NL cohort when compared with the PREVEND 
cohort. 
 Another explanation for this is that we ascertained incident cases differently in 
each cohort. Therefore, we adjusted the KORA basic model for this difference in 
incidence of diabetes between development population and both of our populations. 
Although C-statistics are insensitive to error in average outcome, different 
ascertainment of outcome might have affected discrimination performance of models 
22. However, the incremental predictive value of liver function tests was comparable 
above each model for both cohorts It is worthy to mention that our findings are in 
line with prior evidence on this topic showing minimal to modest prediction 
improvement for risk of future diabetes 5, 7. As a general limitation, we should 
mention that the reclassification improvement is strongly determined by the cut-off 
values for the risk categories. As we have previously explained 34, in the diabetes 
prediction the clinically-relevant cut-off values are not clearly stated yet. In fact, it is 
hard to judge the clinical utility of liver function test at this time. Diagnosis of 
diabetes is always challenging in observational studies because indivduals with type 
2 diabetes may remain undiagnosed for several months to years. Since we used data 
of self-reports, some cases of type 2 diabetes may have been undetected. Finally, the 
PREVEND cohort was enriched with individuals with a higher urinary albumin 
concentration. Therefore, we performed weighted analysis to be able to generalize 
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 our findings to the general population. Further studies are warranted to replicate 
current findings for long-term risk and subsequently evaluate the incremental value 
of liver function tests 10, 28.  
We conclude that a combination of liver function tests can modestly improve 
prediction of medium-term risk of type 2 diabetes above the basic risk model and the 
clinical model incorporating data on glucose and serum uric acid. If data on HbA1c 
are available, these markers of liver injury are of little added predictive value. A 
slightly better improvement in prediction may be present in men.  
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Figure S1. Calibration plots for comparison of the predicted 7.5-year risk of diabetes (according 
to the KORA basic model) against observed risk of developing type 2 diabetes. Panel A (the 
EPIC-NL case-cohort study), Panel B (the PREVEND cohort study). The ‘ideal’ and ‘non-
parametric’ terms, the dashed line denotes the ideal calibration line (slope=1, intercept=0) and the 
dotted line denotes smooth calibration curve for each models. Hosmer-Lemeshow χ2 statistic were 
14.7 (P=0.10) and 7.8 (P=0.56) for the calibration performance of KORA basic model (after 
adjustment for the intercept and the slope) in the EPIC-NL and in the PREVEND studies, 
respectively. 
 
































































 Table S1. Missing data pattern in extrapolated EPIC-NL case-cohort study and PREVEND cohort 
study 












Age 0 0 0 0 
Sex 0 0 0 0 
Incident type 2 diabetes 0 0 0 0 
Weight  20 0.05 77 1.0 
Height  24 0.06 77 1.0 
Body Mass Index  25 0.06 77 1.0 
Smoking  153 0.4 22 0.3 
Family history of diabetes 2234 5.8 601 7.5 
Systolic blood pressure 90 0.2 2 0.02 
Diastolic blood pressure 66 0.17 2 0.02 
History of hypertension 2462 6.4 160 2.0 
Antihypertensive medication 0 0 20 0.3 
Glucose  7889 20.5 54 0.7 
HbA1c 2748 7.2 - - 
Uric acid 2542 6.6 195 2.4 
GGT 2565 6.7 1110 13.9 
AST 2565 6.7 1080 13.5 
ALT 2565 6.7 1080 13.5 
Albumin 2565 6.7 1081 13.5 
EPIC-NL denotes European Prospective Investigation Into Cancer (the Netherlands), PREVEND 
Prevention of Renal and Vascular End-stage Disease, AST, aspartate aminotransferase, ALT, alanine 
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